Giovanna Barba-Spaeth

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8172014/publications.pdf

Version: 2024-02-01

19 papers

2,793 citations

566801 15 h-index 18 g-index

21 all docs

21 docs citations

times ranked

21

5001 citing authors

#	Article	IF	CITATIONS
1	Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nature Immunology, 2016, 17, 1102-1108.	7.0	781
2	Interferons \hat{l}_{\pm} and \hat{l}_{ν} Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics. Gastroenterology, 2006, 131, 1887-1898.	0.6	543
3	Structural basis of potent Zika–dengue virus antibody cross-neutralization. Nature, 2016, 536, 48-53.	13.7	465
4	Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature, 2015, 520, 109-113.	13.7	301
5	Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. Journal of Experimental Medicine, 2005, 202, 1179-1184.	4.2	114
6	Functional and evolutionary insight from the crystal structure of rubella virus protein E1. Nature, 2013, 493, 552-556.	13.7	91
7	Potential Role of Invariant NKT Cells in the Control of Pulmonary Inflammation and CD8+ T Cell Response during Acute Influenza A Virus H3N2 Pneumonia. Journal of Immunology, 2011, 186, 5590-5602.	0.4	88
8	Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6675-6685.	3.3	80
9	Inhibition of Polyamine Biosynthesis Is a Broad-Spectrum Strategy against RNA Viruses. Journal of Virology, 2016, 90, 9683-9692.	1.5	71
10	Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. Nature Communications, 2017, 8, 15411.	5.8	69
11	Yellow fever 17D as a vaccine vector for microbial CTL epitopes. Journal of Experimental Medicine, 2005, 201, 201-209.	4.2	62
12	Dynamic changes in circulating T follicular helper cell composition predict neutralising antibody responses after yellow fever vaccination. Clinical and Translational Immunology, 2020, 9, e1129.	1.7	33
13	Defective viral genomes as therapeutic interfering particles against flavivirus infection in mammalian and mosquito hosts. Nature Communications, 2021, 12, 2290.	5.8	32
14	Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii. Vaccine, 2010, 28, 4644-4652.	1.7	22
15	Sensitive visualization of SARS-CoV-2 RNA with CoronaFISH. Life Science Alliance, 2022, 5, e202101124.	1.3	19
16	FluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D. PLoS ONE, 2022, 17, e0262149.	1.1	6
17	Hepacivirus., 2011,, 473-481.		0
18	Hepacivirus., 2002,, 320-326.		0

#	Article	IF	CITATIONS
19	Hepacivirus., 2002,, 320-326.		O